Patient ID	Patient Name		Birth Date	Sex	Age
SA01366012	TESTINGRNV, REPORTS NORM		1976-08-16	M	48
Order Number	**Client Order Number**	**Ordering Physician**	**Report Notes**		
SA01366012	SA01366012	CLIENT,CLIENT			
Account Information		**Collected**			
C7028846 DLMP Rochester		14 Apr 2025 07:06			

CA 19-9, Peritoneal Fluid

CA 19-9, Peritoneal Fluid

[1] SDL

5 U/mL

A peritoneal fluid CA19–9 concentration = or < 32 U/mL does not rule-out a malignant cause of the ascites or the presence of micro-metastasis. In a study of 137 patients presenting with ascites, malignancies known not to secrete CA19–9 in serum routinely had CA19–9 concentrations = or < 32 U/mL in the peritoneal fluid. In addition, 51% of patients with malignancies known to secrete CA19–9 in serum (pancreatic, breast, gastric, colon, bladder, cholangiocarcinoma, gynecological cancers, peritoneal carcinomatosis, and hepatocellular carcinoma) had a CA19–9 level = or < 32 U/mL. This result should be correlated with serum levels to determine if CA19–9 is elevated in serum. A small percentage of the population does not synthesize CA19–9, or synthesizes low concentrations of the CA19–9 carbohydrate antigen. A low value in these individuals may be uninformative. Peritoneal washings are not an approved specimen type for this assay. Therefore, the interpretive comments for peritoneal fluid do not apply when peritoneal washings are the collected specimen type. Tumor marker tests are not specific for malignancy. This test result should be interpreted in the context of clinical presentation, imaging and cytology findings.

The testing method is an immunoenzymatic assay manufactured by Beckman Coulter Inc. and performed on the UniCel DxI 800.

Values obtained with different assay methods or kits may be different and cannot be used interchangeably.

Test results cannot be interpreted as absolute evidence for the presence or absence of malignant disease.

Site

SDL

Peritoneal Fluid

Received: 15 Apr 2025 09:57 **Reported:** 15 Apr 2025 09:57

Laboratory Notes

[1] This test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
SDL	Mayo Clinic Laboratories - Rochester Superior Drive	3050 Superior Drive NW, Rochester MN 55905	Nikola Baumann Ph.D.	24D1040592